Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Spero Therapeutics (SPRO) Income from Non-Controlling Interests (2016 - 2017)

Historic Income from Non-Controlling Interests for Spero Therapeutics (SPRO) over the last 2 years, with Q4 2017 value amounting to -$6000.0.

  • Spero Therapeutics' Income from Non-Controlling Interests rose 9939.15% to -$6000.0 in Q4 2017 from the same period last year, while for Dec 2017 it was -$1.1 million, marking a year-over-year change of. This contributed to the annual value of -$1.1 million for FY2017, which is 8401.4% up from last year.
  • According to the latest figures from Q4 2017, Spero Therapeutics' Income from Non-Controlling Interests is -$6000.0, which was up 9939.15% from -$8000.0 recorded in Q3 2017.
  • Over the past 5 years, Spero Therapeutics' Income from Non-Controlling Interests peaked at -$6000.0 during Q4 2017, and registered a low of -$1.6 million during Q3 2016.